Screener
Acadia Pharmaceuticals ACAD Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
FAQ
- What is Acadia Pharmaceuticals's retained earnings?
- Acadia Pharmaceuticals (ACAD) reported retained earnings of -$1.78B in Q2 2026.
- How has Acadia Pharmaceuticals's retained earnings changed year-over-year?
- Acadia Pharmaceuticals's retained earnings increased by 17.6% year-over-year, from -$2.16B to -$1.78B.
- What is the long-term trend for Acadia Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's retained earnings has grown at a -1.8% compound annual growth rate (CAGR), from -$1.99B to -$1.81B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Acadia Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude